结核病药物市场：依疾病（活动性结核病、潜伏性结核病）、药物类别（组合药物、第一线抗结核药物、第二线抗结核药物）－2023-2030年全球预测

预计2023年全球抗结核药物市场将达到192972万美元，年复合成长率为6.26%，预计到2030年将出现惊人增长，达到295593万美元。

FPNV定位矩阵

FPNV定位矩阵对于评估全球结核病药物市场至关重要。透过检查业务策略和产品满意度的关键指标，我们对供应商进行全面评估，使您能够根据您的特定需求做出明智的资讯。这种进阶分析将供应商分为四个像限，并取得了不同程度的成功：前沿 (F)、探路者 (P)、利基 (N) 和重要 (V)。

市占率分析

市场占有率分析可以深入了解供应商在特定市场领域的当前地位。比较供应商对总收入、基本客群和其他关键指标的贡献，可以帮助公司更好地了解他们在争夺市场份额时的表现以及面临的情况。该分析还揭示了特定行业的竞争程度、累积和合併的优势以及研究基准年的合併特征。

本报告提供了以下几点见解：

1. 市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2. 市场开发：提供有关利润丰厚的新兴市场的详细资讯，并分析其在成熟市场的渗透率。

3. 市场多元化：提供有关新产品发布、未开发领域、最新发展和投资的详细资讯。

4.市场趋势：全面了解COVID-19、俄罗斯-乌克兰衝突和高通膨的累积影响。

5.竞争评估与资讯：对主要企业的市场占有率、策略、产品、认证、法规状况、专利状况、製造能力等进行综合评估。

6. 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告回答了以下问题：

1.全球结核病药物市场规模及预测为何？

2.在预测期内，COVID-19 对全球结核病治疗药物市场的阻碍因素和影响为何？

3.在预测期内，全球结核病药物市场需要投资哪些产品/细分市场/应用/领域？

4.全球结核病药物市场的竞争策略是什么？

5. 全球结核病药物市场的技术趋势和法律规范是什么？

6.全球结核病药物市场主要厂商的市占率是多少？

7. 哪些型态和策略性措施被认为适合进入全球结核病药物市场？

目录

第1章前言

第2章调查方法

第3章执行摘要

第4章市场概况

第5章市场洞察

• 市场动态
  • 促进因素
    • 全球抗药结核病计画将促进诊断和治疗登记
    • HIV 感染导致 LTBI 病例增加
    • 结核病罹患率上升
  • 抑制因素
    • 耐多药和广泛抗药性结核病药物高成本
  • 机会
    • 加大开发新药研发力度
    • 政府机构扩大结核病宣传活动
  • 任务
    • 结核病药物的副作用
• 市场趋势
• COVID-19 的累积影响
• 俄罗斯-乌克兰衝突的累积影响
• 高通膨的累积效应
• 波特五力分析
• 价值炼和关键路径分析
• 法律规范
• 客户客製化

第6章结核病治疗药物市场：依疾病分类

• 活动性结核病
• 潜伏性结核病

第7章依药物类别分類的结核病药物市场

• 组合药物
• 一线抗结核药物
  • 依三丁醇
  • 异烟肼
  • 吡嗪酰胺
  • 利福平
• 二线抗结核药
  • 捲曲霉素
  • 乙硫异烟胺
  • 左氧氟沙星
  • 链霉素

第8章美洲结核病药物市场

• 阿根廷
• 巴西
• 加拿大
• 墨西哥
• 美国

第9章亚太结核病药物市场

• 澳洲
• 中国
• 印度
• 印尼
• 日本
• 马来西亚
• 菲律宾
• 新加坡
• 韩国
• 台湾
• 泰国
• 越南

第10章欧洲、中东和非洲结核病药物市场

• 丹麦
• 埃及
• 芬兰
• 法国
• 德国
• 以色列
• 义大利
• 荷兰
• 奈及利亚
• 挪威
• 波兰
• 卡达
• 俄罗斯
• 沙乌地阿拉伯
• 南非
• 西班牙
• 瑞典
• 瑞士
• 土耳其
• 阿拉伯聯合大公国
• 英国

第11章竞争形势

• FPNV定位矩阵
• 市占率分析：主要企业
• 竞争情境分析：主要企业

第12章上市公司名单

第13章附录

• 讨论指南
• 关于许可证和定价

The Global Tuberculosis Drugs Market is forecasted to grow significantly, with a projected USD 1,929.72 million in 2023 at a CAGR of 6.26% and expected to reach a staggering USD 2,955.93 million by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Tuberculosis Drugs Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Tuberculosis Drugs Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Disease, market is studied across Active TB and Latent TB. The Active TB is projected to witness significant market share during forecast period.

Based on Drug Class, market is studied across Combination Drugs, First-line Anti-TB Drugs, and Second-line Anti-TB Drugs. The First-line Anti-TB Drugs is further studied across Ethambutol, Isoniazid, Pyrazinamide, and Rifampin. The Second-line Anti-TB Drugs is further studied across Capreomycin, Ethionamide, Levofloxacin, and Streptomycin. The Combination Drugs is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.75% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Tuberculosis Drugs Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Tuberculosis Drugs Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Tuberculosis Drugs Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Tuberculosis Drugs Market?

4. What is the competitive strategic window for opportunities in the Global Tuberculosis Drugs Market?

5. What are the technology trends and regulatory frameworks in the Global Tuberculosis Drugs Market?

6. What is the market share of the leading vendors in the Global Tuberculosis Drugs Market?

7. What modes and strategic moves are considered suitable for entering the Global Tuberculosis Drugs Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Limitations
• 1.7. Assumptions
• 1.8. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

• 4.1. Introduction
• 4.2. Tuberculosis Drugs Market, by Disease, 2022 vs 2030
• 4.3. Tuberculosis Drugs Market, by Drug Class, 2022 vs 2030
• 4.4. Tuberculosis Drugs Market, by Region, 2022 vs 2030

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Global plan against drug-resistant TB drives diagnosis and treatment enrollment
    • 5.1.1.2. HIV burden fuels LTBI case counts
    • 5.1.1.3. Rising prevalence of tuberculosis
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of MDR and XDR TB drugs
  • 5.1.3. Opportunities
    • 5.1.3.1. Increasing research & development of new drug development
    • 5.1.3.2. Growing initiative from government organization for tuberculosis awareness
  • 5.1.4. Challenges
    • 5.1.4.1. Adverse side effects of tuberculosis drugs
• 5.2. Market Trends
• 5.3. Cumulative Impact of COVID-19
• 5.4. Cumulative Impact of Russia-Ukraine Conflict
• 5.5. Cumulative Impact of High Inflation
• 5.6. Porter's Five Forces Analysis
  • 5.6.1. Threat of New Entrants
  • 5.6.2. Threat of Substitutes
  • 5.6.3. Bargaining Power of Customers
  • 5.6.4. Bargaining Power of Suppliers
  • 5.6.5. Industry Rivalry
• 5.7. Value Chain & Critical Path Analysis
• 5.8. Regulatory Framework
• 5.9. Client Customization

6. Tuberculosis Drugs Market, by Disease

• 6.1. Introduction
• 6.2. Active TB
• 6.3. Latent TB

7. Tuberculosis Drugs Market, by Drug Class

• 7.1. Introduction
• 7.2. Combination Drugs
• 7.3. First-line Anti-TB Drugs
  • 7.3.1. Ethambutol
  • 7.3.2. Isoniazid
  • 7.3.3. Pyrazinamide
  • 7.3.4. Rifampin
• 7.4. Second-line Anti-TB Drugs
  • 7.4.1. Capreomycin
  • 7.4.2. Ethionamide
  • 7.4.3. Levofloxacin
  • 7.4.4. Streptomycin

8. Americas Tuberculosis Drugs Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Tuberculosis Drugs Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Tuberculosis Drugs Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. FPNV Positioning Matrix
• 11.2. Market Share Analysis, By Key Player
• 11.3. Competitive Scenario Analysis, By Key Player

12. List of Company Mentioned

13. Appendix

• 13.1. Discussion Guide
• 13.2. License & Pricing

LIST OF FIGURES

• FIGURE 1. TUBERCULOSIS DRUGS MARKET RESEARCH PROCESS
• FIGURE 2. TUBERCULOSIS DRUGS MARKET SIZE, 2022 VS 2030
• FIGURE 3. TUBERCULOSIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2022 VS 2030 (%)
• FIGURE 5. TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2022 VS 2030 (%)
• FIGURE 6. TUBERCULOSIS DRUGS MARKET SIZE, BY REGION, 2022 VS 2030 (%)
• FIGURE 7. TUBERCULOSIS DRUGS MARKET DYNAMICS
• FIGURE 8. TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 9. TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 10. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 11. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 12. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 13. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 14. TUBERCULOSIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2022
• FIGURE 15. TUBERCULOSIS DRUGS MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

• TABLE 1. TUBERCULOSIS DRUGS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
• TABLE 3. TUBERCULOSIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 5. TUBERCULOSIS DRUGS MARKET SIZE, BY ACTIVE TB, BY REGION, 2018-2030 (USD MILLION)
• TABLE 6. TUBERCULOSIS DRUGS MARKET SIZE, BY LATENT TB, BY REGION, 2018-2030 (USD MILLION)
• TABLE 7. TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 8. TUBERCULOSIS DRUGS MARKET SIZE, BY COMBINATION DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 10. TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. TUBERCULOSIS DRUGS MARKET SIZE, BY ETHAMBUTOL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. TUBERCULOSIS DRUGS MARKET SIZE, BY ISONIAZID, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. TUBERCULOSIS DRUGS MARKET SIZE, BY PYRAZINAMIDE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. TUBERCULOSIS DRUGS MARKET SIZE, BY RIFAMPIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 16. TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. TUBERCULOSIS DRUGS MARKET SIZE, BY CAPREOMYCIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. TUBERCULOSIS DRUGS MARKET SIZE, BY ETHIONAMIDE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. TUBERCULOSIS DRUGS MARKET SIZE, BY LEVOFLOXACIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. TUBERCULOSIS DRUGS MARKET SIZE, BY STREPTOMYCIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 26. ARGENTINA TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 27. ARGENTINA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 28. ARGENTINA TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 29. ARGENTINA TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 30. BRAZIL TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 31. BRAZIL TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 32. BRAZIL TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 33. BRAZIL TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 34. CANADA TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 35. CANADA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 36. CANADA TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 37. CANADA TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 38. MEXICO TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 39. MEXICO TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 40. MEXICO TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 41. MEXICO TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 42. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 43. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 44. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 45. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 46. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 47. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 48. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 49. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 50. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 51. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 52. AUSTRALIA TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 53. AUSTRALIA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 54. AUSTRALIA TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 55. AUSTRALIA TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 56. CHINA TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 57. CHINA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 58. CHINA TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 59. CHINA TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 60. INDIA TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 61. INDIA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 62. INDIA TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 63. INDIA TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 64. INDONESIA TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 65. INDONESIA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 66. INDONESIA TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 67. INDONESIA TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 68. JAPAN TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 69. JAPAN TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 70. JAPAN TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 71. JAPAN TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 72. MALAYSIA TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 73. MALAYSIA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 74. MALAYSIA TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 75. MALAYSIA TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 76. PHILIPPINES TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 77. PHILIPPINES TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 78. PHILIPPINES TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 79. PHILIPPINES TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 80. SINGAPORE TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 81. SINGAPORE TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 82. SINGAPORE TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 83. SINGAPORE TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 84. SOUTH KOREA TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 85. SOUTH KOREA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 86. SOUTH KOREA TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 87. SOUTH KOREA TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 88. TAIWAN TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 89. TAIWAN TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 90. TAIWAN TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 91. TAIWAN TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 92. THAILAND TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 93. THAILAND TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 94. THAILAND TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 95. THAILAND TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 96. VIETNAM TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 97. VIETNAM TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 98. VIETNAM TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 99. VIETNAM TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 100. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 101. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 102. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 103. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 104. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 105. DENMARK TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 106. DENMARK TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 107. DENMARK TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 108. DENMARK TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 109. EGYPT TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 110. EGYPT TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 111. EGYPT TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 112. EGYPT TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 113. FINLAND TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 114. FINLAND TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 115. FINLAND TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 116. FINLAND TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 117. FRANCE TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 118. FRANCE TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 119. FRANCE TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 120. FRANCE TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 121. GERMANY TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 122. GERMANY TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 123. GERMANY TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 124. GERMANY TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 125. ISRAEL TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 126. ISRAEL TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 127. ISRAEL TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 128. ISRAEL TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 129. ITALY TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 130. ITALY TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 131. ITALY TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 132. ITALY TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 133. NETHERLANDS TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 134. NETHERLANDS TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 135. NETHERLANDS TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 136. NETHERLANDS TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 137. NIGERIA TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 138. NIGERIA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 139. NIGERIA TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 140. NIGERIA TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 141. NORWAY TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 142. NORWAY TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 143. NORWAY TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 144. NORWAY TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 145. POLAND TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 146. POLAND TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 147. POLAND TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 148. POLAND TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 149. QATAR TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 150. QATAR TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 151. QATAR TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 152. QATAR TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 153. RUSSIA TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 154. RUSSIA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 155. RUSSIA TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 156. RUSSIA TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 157. SAUDI ARABIA TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 158. SAUDI ARABIA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 159. SAUDI ARABIA TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 160. SAUDI ARABIA TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 161. SOUTH AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 162. SOUTH AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 163. SOUTH AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 164. SOUTH AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 165. SPAIN TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 166. SPAIN TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 167. SPAIN TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 168. SPAIN TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 169. SWEDEN TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 170. SWEDEN TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 171. SWEDEN TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 172. SWEDEN TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 173. SWITZERLAND TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 174. SWITZERLAND TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 175. SWITZERLAND TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 176. SWITZERLAND TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 177. TURKEY TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 178. TURKEY TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 179. TURKEY TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 180. TURKEY TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 181. UNITED ARAB EMIRATES TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 182. UNITED ARAB EMIRATES TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 183. UNITED ARAB EMIRATES TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 184. UNITED ARAB EMIRATES TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 185. UNITED KINGDOM TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 186. UNITED KINGDOM TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 187. UNITED KINGDOM TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 188. UNITED KINGDOM TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 189. TUBERCULOSIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2022
• TABLE 190. TUBERCULOSIS DRUGS MARKET SHARE, BY KEY PLAYER, 2022
• TABLE 191. TUBERCULOSIS DRUGS MARKET LICENSE & PRICING